IL315756A - Suppression of the MHC IB-mediated antigen-specific immune system as a novel treatment for type 1 diabetes - Google Patents
Suppression of the MHC IB-mediated antigen-specific immune system as a novel treatment for type 1 diabetesInfo
- Publication number
- IL315756A IL315756A IL315756A IL31575624A IL315756A IL 315756 A IL315756 A IL 315756A IL 315756 A IL315756 A IL 315756A IL 31575624 A IL31575624 A IL 31575624A IL 315756 A IL315756 A IL 315756A
- Authority
- IL
- Israel
- Prior art keywords
- mhc
- diabetes
- antigen
- type
- novel treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164163 | 2022-03-24 | ||
| PCT/EP2023/057681 WO2023180547A1 (en) | 2022-03-24 | 2023-03-24 | Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315756A true IL315756A (en) | 2024-11-01 |
Family
ID=81327177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315756A IL315756A (en) | 2022-03-24 | 2023-03-24 | Suppression of the MHC IB-mediated antigen-specific immune system as a novel treatment for type 1 diabetes |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250205323A1 (https=) |
| EP (1) | EP4499133A1 (https=) |
| JP (1) | JP2025510149A (https=) |
| KR (1) | KR20240167684A (https=) |
| CN (1) | CN118922202A (https=) |
| AU (1) | AU2023238308A1 (https=) |
| CA (1) | CA3255483A1 (https=) |
| CL (1) | CL2024002839A1 (https=) |
| CO (1) | CO2024012945A2 (https=) |
| IL (1) | IL315756A (https=) |
| MX (1) | MX2024011668A (https=) |
| WO (1) | WO2023180547A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3400069A4 (en) * | 2016-01-04 | 2019-09-25 | Cour Pharmaceuticals Development Company Inc. | Particles for the Encapsulation of Fusion Proteins with Bundled Epitopes |
| EP3630809A1 (en) | 2017-05-23 | 2020-04-08 | Bruttel, Valentin | Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation |
-
2023
- 2023-03-24 AU AU2023238308A patent/AU2023238308A1/en active Pending
- 2023-03-24 US US18/849,139 patent/US20250205323A1/en active Pending
- 2023-03-24 CN CN202380029747.7A patent/CN118922202A/zh active Pending
- 2023-03-24 KR KR1020247035504A patent/KR20240167684A/ko active Pending
- 2023-03-24 MX MX2024011668A patent/MX2024011668A/es unknown
- 2023-03-24 CA CA3255483A patent/CA3255483A1/en active Pending
- 2023-03-24 EP EP23714707.9A patent/EP4499133A1/en active Pending
- 2023-03-24 WO PCT/EP2023/057681 patent/WO2023180547A1/en not_active Ceased
- 2023-03-24 JP JP2024556464A patent/JP2025510149A/ja active Pending
- 2023-03-24 IL IL315756A patent/IL315756A/en unknown
-
2024
- 2024-09-23 CL CL2024002839A patent/CL2024002839A1/es unknown
- 2024-09-25 CO CONC2024/0012945A patent/CO2024012945A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023180547A1 (en) | 2023-09-28 |
| EP4499133A1 (en) | 2025-02-05 |
| JP2025510149A (ja) | 2025-04-14 |
| CA3255483A1 (en) | 2023-09-28 |
| CO2024012945A2 (es) | 2024-10-31 |
| CN118922202A (zh) | 2024-11-08 |
| AU2023238308A1 (en) | 2024-10-10 |
| MX2024011668A (es) | 2024-09-27 |
| KR20240167684A (ko) | 2024-11-27 |
| CL2024002839A1 (es) | 2025-02-21 |
| US20250205323A1 (en) | 2025-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308628A (en) | Methods for treating type 1 diabetes | |
| GB202212641D0 (en) | Novel compounds | |
| IL315756A (en) | Suppression of the MHC IB-mediated antigen-specific immune system as a novel treatment for type 1 diabetes | |
| GB202300833D0 (en) | Novel compounds | |
| IL314754A (en) | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo | |
| IL315510A (en) | MHC IB-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and MOG antibody disease | |
| GB202307426D0 (en) | Novel compounds | |
| GB202302686D0 (en) | Novel compounds | |
| GB202217575D0 (en) | Novel compounds | |
| GB202216323D0 (en) | Novel compounds | |
| GB202206054D0 (en) | Novel Compounds | |
| GB201913408D0 (en) | Proinsulin peptides for type 1 diabetes | |
| CA3305590A1 (en) | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo | |
| CA3305594A1 (en) | Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease | |
| PH32022050326S1 (en) | Wearable autoinjector | |
| GB202317236D0 (en) | Novel compounds | |
| GB202316973D0 (en) | Novel compounds | |
| GB202316972D0 (en) | Novel compounds | |
| GB202316971D0 (en) | Novel compounds | |
| GB202316975D0 (en) | Novel compounds | |
| GB202316974D0 (en) | Novel compounds | |
| GB202315015D0 (en) | Novel compounds | |
| GB202310218D0 (en) | Novel compounds | |
| GB202310221D0 (en) | Novel compounds | |
| GB202308147D0 (en) | Novel compounds |